After two CRLs, FDA approves scPharmaceuticals' drug-device as biotech nabs $100M to fund launch

Paul Schloesser

Associate Editor

FDA has finally accepted scPharmaceuticals’ product for approval — and the company is now hunting the money to push it to market.
scPharmaceuticals made a dual …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After two CRLs, FDA approves scPharmaceuticals' drug-device as biotech nabs $100M to fund launch

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter two CRLs, FDA ap­proves scPhar­ma­ceu­ti­cal­s' drug-de­vice as biotech nabs $100M to fund launch

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After two CRLs, FDA approves scPharmaceuticals' drug-device as biotech nabs $100M to fund launch